

Serial No.: 09/849,602  
Conf. No.: 8884

- 2 -

Art Unit: 1631

In the Claims

Applicants have submitted a new complete claim set showing marked up claims with insertions indicated by underlining and deletions indicated by strikeouts and/or double bracketing.

Please cancel claims 3, 6, 20, 51, 56, 57, 60, and 90 without prejudice or disclaimer.

Please amend pending claims 1, 15, 47, 86, and 98 as noted below.

1. (Currently Amended) A method for diagnosing colon cancer in a subject comprising:  
obtaining a biological sample from a subject,  
contacting the sample with at least two different colon cancer-associated polypeptides encoded by nucleic acid molecules comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:~~1-15~~ 1 and 5, and  
determining specific binding between the colon cancer-associated polypeptides and agents in the sample, wherein the presence of specific binding is diagnostic for colon cancer in the subject.
2. (Original) The method of claim 1, wherein the sample is blood.
3. (Cancelled)
4. (Previously Presented) The method of claim 1, wherein the agents are antibodies or antigen-binding fragments of an antibody.
- 5-14. (Cancelled)
15. (Currently Amended) A method for determining onset, progression, or regression, of colon cancer in a subject, comprising:  
obtaining from a subject a first biological sample,

752223.1

Serial No.: 09/849,602  
Conf. No.: 8884

- 3 -

Art Unit: 1631

contacting the first sample with at least two different colon cancer-associated polypeptides encoded by nucleic acid molecules comprising a nucleotide sequence selected from ~~form~~ the group consisting of SEQ ID NOs:~~1-15~~ 1 and 5,

determining specific binding between agents in the first sample and the at least two different colon cancer-associated polypeptides,

obtaining subsequently from a ~~the~~ subject a second biological sample,

contacting the second biological sample with at least two different colon cancer-associated polypeptides encoded by nucleic acid molecules comprising a nucleotide sequence selected from ~~form~~ the group consisting of SEQ ID NOs:~~1-15~~ 1 and 5,

determining specific binding between agents in the second sample and the at least two different colon cancer-associated polypeptides, and

comparing the determination of binding in the first sample to the determination of specific binding in the second sample as a determination of the onset, progression, or regression of the colon cancer.

16. (Original) The method of claim 15, wherein the sample is a blood sample.

17-46. (Cancelled)

47. (Currently Amended) A kit for the diagnosis of colon cancer in a subject, comprising: at least two different colon cancer-associated polypeptides encoded by nucleic acid molecules comprising a nucleotide sequence selected from the group consisting of: SEQ ID NOs:~~1-15~~ 1 and 5, one or more control antigens, and instructions for the use of the polypeptides in the diagnosis of colon cancer.

48. (Original) The kit of claim 47, wherein the colon cancer-associated polypeptides are bound to a substrate.

49-85. (Cancelled)

752223.1

Serial No.: 09/849,602  
Conf. No.: 8884

- 4 -

Art Unit: 1631

86. (Currently Amended) A method for diagnosing cancer in a subject comprising:  
obtaining a biological sample from a subject,  
contacting the sample with a colon cancer-associated polypeptide encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1,2, and 5, and 6, and  
determining specific binding between the colon cancer-associated polypeptide and agents in the sample, wherein the presence of specific binding is diagnostic for cancer in the subject.

87. (Original) The method of claim 86, wherein the sample is blood.

88. (Previously Presented) The method of claim 86, wherein the agents are antibodies or antigen-binding fragments of an antibody.

89. (Original) The method of claim 86, wherein the cancer is colon cancer.

90-97. (Cancelled)

98. (Currently Amended) A method for determining onset, progression, or regression, of cancer in a subject, comprising:  
obtaining from a subject a first biological sample,  
contacting the first sample with a colon cancer associated polypeptide encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1,2, and 5, and 6,  
determining specific binding between agents in the first sample and the colon cancer-associated,  
obtaining subsequently from ~~a~~ the subject a second biological sample,  
contacting the second sample with a colon cancer associated polypeptide encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1,2, and 5, and 6,

752223.1

Serial No.: 09/849,602  
Conf. No.: 8884

- 5 -

Art Unit: 1631

determining specific binding between agents in the second sample and the colon cancer-associated polypeptide, and

comparing the determination of binding in the first sample to the determination of specific binding in the second sample as a determination of the onset, progression, or regression of cancer.

99-154. (Cancelled)

752223.1